

## Review Article

# Oxidative Status in Etiology of Type 2 Diabetes

Il'yasova D\*

Division of Epidemiology and Biostatistics, School of Public Health, Georgia State University, USA

\*Corresponding author: Dora Il'yasova, Division of Epidemiology and Biostatistics, School of Public Health, Georgia State University, PO Box 3995, Atlanta, GA 30302-3995; Tel: 404-413-1135; Email: dilyasova@gsu.edu

Received: October 08, 2014; Accepted: March 31, 2015; Published: April 02, 2015

## Abstract

This review focuses on the relationship between oxidative status as measured by the systemic levels of lipid peroxidation markers F2-isoprostanes and etiology of type 2 diabetes. Elevated levels of F2-isoprostanes were found in obesity, insulin resistance, impaired glucose tolerance and type 2 diabetes. It was hypothesized that increased F2-isoprostane levels reflect the obesity-induced oxidative stress that promotes the development of type 2 diabetes. The most convincing evidence against such an interpretation is the well-accepted role of physical activity in protecting against type 2 diabetes, given that physical activity increases F2-isoprostane levels. Adding to this evidence, the prospective studies show that individuals with higher levels of urinary F2-isoprostanes have a lower risk of weight gain and type 2 diabetes, thereby directly contradicting the etiological relevance of elevated oxidative status in diabetes etiology. This review examines a new interpretation of F2-isoprostane levels as reflecting intensity of oxidative metabolism, a major endogenous source of reactive oxygen species, and specifically, the intensity of fat oxidation.

**Keywords:** F2-isoprostanes; Obesity; Type 2 diabetes; Epidemiology; Oxidative metabolism

## Abbreviations

BMI: Body Mass Index; ROS: Reactive Oxygen Species

## Oxidative Status


All aerobic organisms are constantly exposed to Reactive Oxygen Species (ROS) generated either by endogenous processes, such as cellular respiration and antibacterial defense, or by external oxidative exposures, such as ionizing radiation, smoking, and toxins [1]. ROS are highly reactive molecules that oxidize DNA, lipids, and proteins [1]. To counteract their damaging effects, aerobic organisms have developed multiple antioxidant defense systems [1]. Theoretically, ROS production and antioxidant defense set constitutive levels of oxidative status within cells, tissues, and at the systemic level. Whether or not this assumption is correct at the tissue level remains to be determined. However, the systemic levels of oxidative status measured by biomarkers of lipid peroxidation, F2-isoprostanes [2,3], represents a constitutive individual characteristic [4,5]. F2-isoprostanes are the only biomarkers of oxidative status that have been validated against established oxidative stressors in animal [6] and clinical [7] models. Thus, this review will focus on the relationship between F2-isoprostanes and type 2 diabetes as well as diabetes risk factors. Importantly, similar to other individual characteristics, such as BMI and blood pressure, the levels of urinary F2-isoprostanes can change within an individual during the lifetime. Such modifiable factors are important for epidemiological research, because – as opposed to unmodifiable factors (age, gender, and genetics) – they can be targeted by prevention strategies. This consideration is especially important for etiology of type 2 diabetes, a disease that proved to be preventable [8]. If elevated oxidative status promotes the development of type 2 diabetes, the disease could be prevented by reducing oxidative status via lifestyle modifications and/or pharmacological interventions. This consideration stimulated research of the relationships between oxidative status and type 2 diabetes as well as its risk factors.

## Oxidative status and type 2 diabetes

The cross-sectional studies show direct association between systemic F2-isoprostane levels and type 2 diabetes [9-16]. Also, the early stage of diabetes, impaired glucose tolerance [12,17,18], the hallmark of diabetes etiology insulin resistance [19], and its main risk factor obesity [12,20,21] – all are associated with elevated systemic levels of F2-isoprostanes cross-sectionally. Naturally, these cross-sectional associations can be interpreted as evidence that elevated F2-isoprostane levels promote the development of type 2 diabetes.

However, three lines of evidence strongly contradict such a hypothesis. The first is related to the assumption that antioxidant supplementation can shift pro-/antioxidant balance and thereby, prevent type 2 diabetes. This assumption and the aforementioned cross-sectional findings encouraged several randomized trials of type 2 diabetes prevention. Contrary to expectations, all large randomized trials of antioxidant supplementation failed to prevent type 2 diabetes [22-28]. In fact, a systematic review of the overall mortality in antioxidant trials concluded that “Beta-carotene and vitamin E seem to increase mortality, and so may higher doses of vitamin A” [29]. Failure to prevent diabetes by antioxidant supplementation questions the hypothesis that elevated oxidative status promotes the development of type 2 diabetes.

The second line of evidence is related to physical exercise as one of the best preventive strategies in type 2 diabetes prevention [30,31]. Physical exercise undeniably increases F2-isoprostane levels for at least several hours [32]; whereas an increase in the basal levels of these biomarkers has been demonstrated only in some populations [33]. Over the years a sustained exercise training exposes an individual to repetitive sharp increases in oxidative status. Thus, there is a contradiction between the suggested harmful role of high oxidative status on one hand and the protective role of physical exercise that increases oxidative status on the other hand. Dr. James



**Figure 1:** Proposed relationships between urinary F2-isoprostanes and fatty acid oxidation rates.

Watson published a biological hypothesis explaining why increased generation of ROS by physical exercise prevents the development of type 2 diabetes, namely by generating a “sufficient redox potential for disulfide bonds to be formed” [34].

The third and the ultimate line of evidence of a protective instead of causal role of elevated systemic F2-isoprostanes in etiology of type 2 diabetes come from the prospective studies. In two cohorts, elevated levels of F2-isoprostanes predicted lower risk of weight gain [21,35]. Moreover, high levels of F2-isoprostanes predicted lower risk of type 2 diabetes [36]. These prospective findings refute the hypothesis that elevated F2-isoprostane levels promote the development of type 2 diabetes. Hence, the prospective and cross-sectional data show opposite directions of the associations between F2-isoprostane levels and type 2 diabetes. How can this be explained?

The existing cross-sectional and prospective findings can be reconciled within the framework of a compensatory function. Within this framework, systemic levels of F2-isoprostanes can be interpreted as reflecting a compensatory mechanism that is related to etiology of obesity and type 2 diabetes.

**Regulation of energy balance as a framework for understanding the connection between oxidative status and type 2 diabetes etiology**

A compensatory mechanism involved in the maintenance of energy balance can explain the opposite direction of the cross-sectional and prospective associations between F2-isoprostane levels and obesity and type 2 diabetes risks.

Generally, a stable body weight constitutes balanced energy intake and energy expenditure. Positive energy balance occurs when energy intake exceeds energy expenditure and is manifested as an increase in body mass, with the majority of the gained mass being fat mass [37,38]. Correspondingly, negative energy balance occurs when energy expenditure exceeds energy intake and is manifested as a loss of body mass, with fat mass loss being the predominant component of this change as well. A physiological control of energy balance promotes shifts in energy expenditure to counteract both negative energy balance (by a decrease in energy expenditure) and positive energy balance (by an increase in energy expenditure). With fat mass being the predominant element of body mass changes, it is not surprising that fat oxidation plays an essential role in physiological

control of energy balance [37-41]. Accordingly, in obese individuals the levels of fat oxidation rates on average are higher as a result of fat mass gain; and conversely, weight loss is associated with a decrease in fat oxidation rates. At the same time, efficient fat oxidation lowers the risk of weight gain and thereby, the risk of obesity and type 2 diabetes [37-41] (Figure 1). Thus, fat oxidation rates are positively associated with obesity and type 2 diabetes (fat oxidation rates increase in type 2 diabetes also as a result of diminished ability to use glucose as a fuel source), whereas intensive fat oxidation reduces the risk of both conditions.

Is there a connection between F2-isoprostanes and fat oxidation rates? Such connection would explain the increased levels of F2-isoprostanes among obese individuals and diabetics as well as lower risks of weight gain and type 2 diabetes among individuals with elevated levels of these biomarkers [42].

**Systemic levels of F2-isoprostanes and fatty acid oxidation**

As biomarkers of systemic ROS levels, F2-isoprostanes are likely to reflect intensity of mitochondrial metabolism, which represents the major endogenous source of ROS (1). A connection between oxidative metabolism and F2-isoprostane levels can explain the observed increase in F2-isoprostanes during physical exercise as a reflection of increased oxidative metabolism and fatty acid oxidation specifically. Fatty acid oxidation increases with moderate physical activity as fat is the predominant contributor to muscle fuel metabolism; vice-versa muscles are the major organ for free fatty acid disposal [43-46]. Correspondingly, glucose uptake by skeletal muscle in the basal state accounts for only a small percentage of total glucose disappearance and only a minor proportion of peripheral oxygen consumption [47]. This suggests that the intensity of fatty acid oxidation by skeletal muscle is likely to determine whether an individual has higher or lower systemic ROS (and F2-isoprostane) levels. The fact that mitochondrial fatty acid oxidation produces higher levels of ROS as compared to glycolytic substrates [48] strongly supports the connection between increased oxidative status and intensive fat oxidation.

These hypothesized relationships between systemic F2-isoprostanes levels and fatty acid metabolism are further reinforced by several circumstantial evidence. For example, fat oxidation and urinary F2-isoprostanes both decrease in response to weight loss

[37,38,48]. Similar parallel relationships are found in racial groups: African Americans have lower levels of fat oxidation [49], and also lower levels of urinary F2-isoprostanes [50]. Furthermore, the rates of obesity and type 2 diabetes are greater among African Americans and low levels of fat oxidation are proposed as a metabolic trait predisposing African Americans to these conditions [49]. Other supporting evidence is the correlation between fasting levels of non-esterified fatty acids, that are known to stimulate fatty acid oxidation in skeletal muscles [43-46], and urinary F2-isoprostanes [51]. However, to the best of the author's knowledge, no direct evidence have been published that urinary F2-isoprostanes relates to the intensity of fat oxidation. For example, the proposed hypothesis predicts inverse relationship between respiratory quotient (low respiratory quotient indicates higher proportion of fat oxidation in fuel metabolism) and urinary F2-isoprostanes.

Within this framework (Figure 1), the well-established cross-sectional direct association of F2-isoprostane levels with obesity can be seen to represent a long-term adaptation to higher adiposity through increased fat oxidation. At the same time, slow fat oxidation – reflected by low urinary F2-isoprostane levels – would lead to weight gain. In the case of weak long-term adaptation, the cycle of increasing adiposity should persist, leading to the obesity-driven development of type 2 diabetes. Of importance, F2-isoprostane levels among African Americans showed no association with adiposity (measured as BMI), whereas a direct cross-sectional association with BMI was clearly evident among Caucasians [50]. This disconnect between F2-isoprostane levels and BMI in African Americans may signify weak long-term adaptation to higher adiposity, which potentially could help to explain the greater type 2 diabetes rates among African Americans.

## Conclusion

Commonly, a statistically significant elevation of oxidative status markers has been interpreted as harmful oxidative stress [52]. A prominent example is the conventional view that the elevated F2-isoprostane levels in obesity represent obesity-induced oxidative stress and a mechanistic link between obesity and the risks of type 2 diabetes [53] and cardiovascular disease [54]. The most convincing evidence against such an interpretation is the well-accepted role of physical activity in protecting against the development of both type 2 diabetes and cardiovascular disease [31,55], given that physical activity actually increases F2-isoprostane levels at least for several hours. Adding to this evidence, the prospective studies show that individuals with higher levels of urinary F2-isoprostanes have a lower risk of weight gain [21,35] and type 2 diabetes [36]. These findings directly contradict the hypothesis that high oxidative status has etiological relevance in the development of diabetes; in fact, they suggest just the opposite – that an increase in F2-isoprostane levels may be beneficial in preventing diabetes and obesity. Congruent to these observations, multiple antioxidant supplementation trials so far have failed to prevent cardiovascular disease or type 2 diabetes [22-29]. Thus, the accumulating body of evidence emphasizes the need for a new interpretation of systemic oxidative status markers. The focus on fat oxidation as a physiological determinant of F2-isoprostane levels connects and sheds light on several observations that are otherwise unexplainable [42]. This hypothesis however does not rule

out a possibility that locally elevated reactive oxygen/nitrogen species at the tissue level may promote development of pathological changes; but it argues that local oxidative stress contributes insignificantly to the systemic levels of oxidative status. Then, the systemic levels of F2-isoprostanes can be viewed as a beneficial metabolic trait reflecting healthy mitochondrial metabolism and fatty acid oxidation rates, allowing an effective physiological control of energy balance and thereby preventing obesity and type 2 diabetes.

## References

- Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 4<sup>th</sup> edn. Oxford University Press, Oxford. 2007.
- Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced *in vivo* in humans by a noncyclooxygenase, free radical-catalyzed mechanism. *Proc Natl Acad Sci USA*. 1990; 87: 9383–9387.
- Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress *in vivo*. *Free Radic Biol Med*. 2000; 28: 505–513.
- Wu X, Cai H, Xiang YB, Cai Q, Yang G, Liu D, et al. Intra-person variation of urinary biomarkers of oxidative stress and inflammation. *Cancer Epidemiol Biomarkers Prev*. 2010; 19: 947–952.
- Zhang H, Ilyasova D, Sztaray J, Young SP, Wang F, Millington DS. Quantification of the oxidative damage biomarker 2,3-dinor-8-isoprostaglandin-F(2alpha) in human urine using liquid chromatography–tandem mass spectrometry. *Anal Biochem*. 2010; 399: 302–304.
- Kadiiska MB, Gladen BC, Baird DD, Germolec D, Graham LB, Parker CE, et al. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? *Free Radic Biol Med* 2005; 38: 698–710.
- Ilyasova D, Spasojevic I, Wang F, Tolun AA, Base K, Young SP, et al. Urinary biomarkers of oxidative status in a clinical model of oxidative assault. *Cancer Epidemiol Biomarkers Prev*. 2010; 19: 1506–1510.
- Mozaffarian D, Kamineni A, Carnethon M, Djoussé L, Mukamal KJ, Siscovick D. Lifestyle risk factors and new-onset diabetes mellitus in older adults: the cardiovascular health study. *Arch Intern Med*. 2009; 169: 798-807.
- Gopaul NK, Anggård EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. *FEBS Lett*, 1995; 368: 225-229.
- Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, et al. *In vivo* formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. *Circulation*. 1999; 99: 224-229.
- Devaraj S, Hirany SV, Burk RF, Jialal I. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. *Clin Chem*. 2001; 47: 1974-1979.
- Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. *ArteriosclerThrombVasc Biol*. 2003; 23: 434-439.
- De Cristofaro R, Rocca B, Vitacolonna E, Falco A, Marchesani P, Ciabattoni G, et al. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. *J ThrombHaemost*. 2003; 1: 250-256.
- Davi G, Falco A, Patrono C. Lipid peroxidation in diabetes mellitus. *Antioxid Redox Signal*. 2005; 7: 256-268.
- Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M, Kohno N. A protective effect of adiponectin against oxidative stress in Japanese Americans: the association between adiponectin or leptin and urinary isoprostane. *Metabolism*. 2005; 54: 194-199.
- Nobecourt E, Jacqueminet S, Hansel B, Chantepie S, Grimaldi A, Chapman MJ, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. *Diabetologia*. 2005; 48: 529-538.

17. Gopaul NK, Manraj MD, Hébé A, Lee Kwai Yan S, Johnston A, Carrier MJ, et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. *Diabetologia*. 2001; 44: 706-712.
18. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, et al. Factors associated with oxidative stress in human populations. *Am J Epidemiol*. 2002; 156: 274-285.
19. Dorjgochoo T1, Gao YT, Chow WH, Shu XO, Yang G, Cai Q, et al. Obesity, age, and oxidative stress in middle-aged and older women. *Antioxid Redox Signal*. 2011; 14: 2453-2460.
20. Ilyasova D, Wang F, Spasojevic I, Base K, D'Agostino RB Jr, Wagenknecht LE. Urinary F2-isoprostanes, obesity, and weight gain in the IRAS cohort. *Obesity*. 2012; 20: 1915-1921.
21. Meigs JB, Larson MG, Fox CS, Keaney JF Jr, Vasan RS, Benjamin EJ. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham Offspring Study. *Diabetes Care*. 2007; 30: 2529-2535.
22. Liu S, Ajani U, Chae C, Hennekens C, Buring JE, Manson JE. Long-term beta-carotene supplementation and risk of type 2 diabetes mellitus: a randomized controlled trial. *JAMA*. 1999; 282: 1073-1075.
23. Liu S, Lee IM, Song Y, Van Denburgh M, Cook NR, Manson JE, et al. Vitamin E and risk of type 2 diabetes in the women's health study randomized controlled trial. *Diabetes*. 2006; 55: 2856-2862.
24. Wang L, Liu S, Pradhan AD, Manson JE, Buring JE, Gaziano JM, et al. Plasma lycopene, other carotenoids, and the risk of type 2 diabetes in women. *Am J Epidemiol*. 2006; 164: 576-585.
25. Kataja-Tuomola M, Sundell JR, Männistö S, Virtanen MJ, Kontto J, Albanes D, et al. Effect of alpha-tocopherol and beta-carotene supplementation on the incidence of type 2 diabetes. *Diabetologia*. 2008; 51: 47-53.
26. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, et al. Effects of Long-Term Selenium Supplementation on the Incidence of Type 2 Diabetes: A Randomized Trial. *Ann Intern Med*. 2007; 147: 217-223.
27. Czernichow S, Couthous A, Bertrais S, Vergnaud AC, Dauchet L, Galan P, et al. Antioxidant supplementation does not affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and Minerals (SU.VI.MAX) study in France: association with dietary intake and plasma concentrations. *Am J Clin Nutr*. 2006; 84: 395-399.
28. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *Diabetes Care*. 2002; 25: 148-198.
29. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. *Cochrane Database Syst Rev*. 2012; 3: CD007176.
30. Sanz C, Gautier JF, Hanaire H. Physical exercise for the prevention and treatment of type 2 diabetes. *Diabetes Metab*. 2010; 36: 346-351.
31. Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. *Diabetes Care*. 2010; 33: e147-167.
32. Margonis K, Fatouros IG, Jamurtas AZ, Nikolaidis MG, Douroudos I, Chatzinikolaou A, et al. Oxidative stress biomarkers responses to physical overtraining: implications for diagnosis. *Free Radic Biol Med*. 2007; 43: 901-910.
33. Jones LW, Eves ND, Spasojevic I, Wang F, Ilyasova D. Effects of aerobic training on oxidative status in postsurgical non-small cell lung cancer patients: a pilot study. *Lung Cancer*. 2011; 72: 45-51.
34. Watson JD. Type 2 diabetes as a redox disease. *Lancet*. 2014; 383: 841-843.
35. Kanaya AM, Wassel CL, Stoddard PJ, Harris TB, Cummings SR, Kritchevsky SB, et al. F2-isoprostanes and adiposity in older adults. *Obesity*. 2011; 19: 861-867.
36. Ilyasova D, Spasojevic I, Base K, Zhang H, Wang F, Young SP, et al. Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes. *Diabetes Care*. 2012; 35: 173-174.
37. Ravussin E, Smith SR. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. *Ann N Y Acad Sci*. 2002; 967: 363-378.
38. Hill JO, Wyatt HR, Peters JC. Energy balance and obesity. *Circulation*. 2012; 126: 126-132.
39. Schutz Y, Tremblay A, Weinsier RL, Nelson KM. Role of fat oxidation in the long-term stabilization of body weight in obese women. *Am J Clin Nutr*. 1992; 55: 670-674.
40. Weyer C, Pratley RE, Salbe AD, Bogardus C, Ravussin E, Tataranni PA. Energy expenditure, fat oxidation, and body weight regulation: A study of metabolic adaptation to long-term weight change. *J Clin Endocrinol Metab*. 2000; 85: 1087-1094.
41. McGarry JD. Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. *Diabetes*. 2002; 51: 7-18.
42. Ilyasova D, Morrow JD, Wagenknecht LE. Urinary F2-isoprostanes are not associated with increased risk of type 2 diabetes. *Obesity Res*. 2005; 13: 1638-1644.
43. Andres R, Cader G, Zierler KL. The quantitatively minor role of carbohydrate in oxidative metabolism by skeletal muscle in intact man in the basal state; measurements of oxygen and glucose uptake and carbon dioxide and lactate production in the forearm. *J Clin Invest*. 1956; 35: 671-682.
44. Baltzan MA, Andres R, Cader G, Zierler KL. Heterogeneity of forearm metabolism with special reference to free fatty acids. *J Clin Invest*. 1962; 41: 116-125.
45. Tancredi RG, Dagenais GR, Zierler KL. Free fatty acid metabolism in the forearm at rest: muscle uptake and adipose tissue release of free fatty acids. *Johns Hopkins Med J*. 1976; 138: 167-179.
46. Jackson RA, Hamling JB, Blix PM, Nabarro JD. Relationship among peripheral glucose uptake, oxygen consumption, and glucose turnover in postabsorptive man. *J Clin Endocrinol Metab*. 1984; 59: 857-860.
47. Quinlan CL, Perevoshchikova IV, Hey-Mogensen M, Orr AL, Brand MD. Sites of reactive oxygen species generation by mitochondria oxidizing different substrates. *Redox Biol*. 2013; 1: 304-312.
48. Davi G, Guagnano MT, Ciabattini G, Basili S, Falco A, Marinopicolli M, et al. Platelet activation in obese women: role of inflammation and oxidant stress. *JAMA*. 2002; 288: 2008-2014.
49. Weyer CSnitzer S, Bogardus C, Ravussin E. Energy metabolism in African Americans: potential risk factors for obesity. *Am J Clin Nutr*. 1999; 70: 13-20.
50. Ilyasova D, Wang F, Spasojevic I, Base K, D'Agostino RB Jr, Wagenknecht LE. Racial differences in urinary F2-isoprostane levels and the cross-sectional association with BMI. *Obesity*. 2012; 20: 2147-2150.
51. Ilyasova D, Wang F, D'Agostino RB Jr, Hanley A, Wagenknecht LE. Prospective association between fasting NEFA and type 2 diabetes: impact of post-load glucose. *Diabetologia*. 2010; 53: 866-874.
52. Basu S. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. *Antioxid Redox Signal*. 2008; 10: 1405-1434.
53. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. *Free Radic Biol Med*. 2011; 50: 567-575.
54. Otani H. Oxidative Stress as Pathogenesis of Cardiovascular Risk Associated with Metabolic Syndrome. *Antioxid Redox Signal*. 2011; 15: 1911-1926.
55. Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. *Obesity*. 2009; 17: S43-S48.